Enanta Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ENTA Nasdaq 2834 www.enanta.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences - Nov 4th, 2025 5:00 am
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has caught the attention of institutional investors who hold a sizeable 44% stake - Nov 4th, 2025 4:40 am
Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025 - Oct 20th, 2025 5:00 am
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025 - Oct 7th, 2025 5:00 am
Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Oct 2nd, 2025 2:01 pm
Traders Weigh US Government Shutdown, Fueling Premarket Losses for US Equity Futures - Oct 1st, 2025 7:10 am
FDA official’s comments spark Aurinia sell-off; Halozyme buys a biotech - Oct 1st, 2025 4:00 am
Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock - Sep 30th, 2025 7:00 pm
Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock - Sep 30th, 2025 2:11 pm
Enanta stock doubles despite RSV trial missing primary endpoint - Sep 30th, 2025 4:58 am
Enanta's RSV Pill Shows Promise In Cutting Recovery Time For High-Risk Adults - Sep 29th, 2025 11:28 am
Enanta Pharmaceuticals Says Zelicapavir Misses Phase 2 Primary Endpoint, But Shows RSV Improvement - Sep 29th, 2025 6:20 am
Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults - Sep 29th, 2025 4:30 am
Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults - Sep 26th, 2025 2:01 pm
Enanta CFO dies after taking medical leave of absence - Sep 3rd, 2025 8:46 am
Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr. - Sep 3rd, 2025 4:00 am
Does Enanta’s EU Lawsuit Over Paxlovid Shift the Bull Case for Pfizer (PFE)? - Aug 28th, 2025 4:09 am
Enanta Files Patent Lawsuit Against Pfizer (PFE) Over COVID-19 Drug Paxlovid - Aug 21st, 2025 11:41 am
Enanta Pharmaceuticals to Participate in September Investor Conferences - Aug 21st, 2025 5:00 am
Pfizer battles another Paxlovid lawsuit from Enanta - Aug 20th, 2025 10:53 am